Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,IMUX,125815000,21749400,11176000,,-11159000,,-11159000,3014000,0,-14190000,-14190000,,,,,,0,0,14190000,0,3031000,,-11159000,-11159000,266823000,9076000,158785000,85000,167861000,2000,-103928000,32970000,-4112000,42000,127452000,8397000,-4112000,1104000,133745000,1643000,3700000,125000,-24000,8111000,-1695000,8338000,-5731000,145000,-13963000,-24000,-227000,-1210000,-24000,125348000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,9.93,1630526403,0.07999992,9.88,10.18,9.74,82819,"Immunic, Inc.",NMS,PRE,-0.24559027,0,False,False,0.81218195,9.74 - 10.18,9.85,0.0,0.0,8,9,finmb_403013221,NasdaqGS,"Immunic, Inc.",USD,236998,156457,2.2400002,0.29128742,7.69 - 28.214,-18.284,-0.6480471,7.69,28.214,1555286400,1614346200,1614346200,1614346200,-2.81,-3.66,2,-3.96,-2.5075758,7.501,9.436571,0.49342918,0.052289035,13.162609,-3.2326088,215971552,-2.7131147,1.3238236,15,America/New_York,EDT,-14400000,2.03,,,28.21,7.69,9.44,13.16,237k,156.46k,21.75M,,14.09M,29.67%,46.06%,1.45M,9.05,7.68%,6.68%,931.78k,,,,,,0.00%,"Apr 14, 2019",,1:40,"Apr 14, 2019","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-26.18%,-40.54%,,,,,-48.93M,-44.02M,-2.81,,127.45M,6.02,973k,0.61,15.93,7.50,-46.12M,-30.37M,Value,10036,Healthcare,28,10,5,"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",New York,332 255 9818,NY,9,1577750400,1619740800,10,United States,http://www.immunic-therapeutics.com,86400,10,1200 Avenue of the Americas,Biotechnology,Suite 200
t-1,IMUX,129905000,21749400,11040000,,-12913000,,-12913000,2505000,0,-13545000,-13545000,,,,,,0,0,13545000,0,632000,,-12913000,-12913000,257394000,8765000,162875000,93000,171640000,2000,-92769000,32970000,-1752000,42000,133183000,8030000,-1752000,1087000,137541000,1108000,3419000,1551000,-63000,96540000,-1293000,103505000,84576000,4000,-11905000,43000,-6965000,707000,-63000,129511000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,9.93,1630526403,0.07999992,9.88,10.18,9.74,82819,"Immunic, Inc.",NMS,PRE,-0.24559027,0,False,False,0.81218195,9.74 - 10.18,9.85,0.0,0.0,8,9,finmb_403013221,NasdaqGS,"Immunic, Inc.",USD,236998,156457,2.2400002,0.29128742,7.69 - 28.214,-18.284,-0.6480471,7.69,28.214,1555286400,1614346200,1614346200,1614346200,-2.81,-3.66,2,-3.96,-2.5075758,7.501,9.436571,0.49342918,0.052289035,13.162609,-3.2326088,215971552,-2.7131147,1.3238236,15,America/New_York,EDT,-14400000,2.03,,,28.21,7.69,9.44,13.16,237k,156.46k,21.75M,,14.09M,29.67%,46.06%,1.45M,9.05,7.68%,6.68%,931.78k,,,,,,0.00%,"Apr 14, 2019",,1:40,"Apr 14, 2019","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-26.18%,-40.54%,,,,,-48.93M,-44.02M,-2.81,,127.45M,6.02,973k,0.61,15.93,7.50,-46.12M,-30.37M,Value,10036,Healthcare,28,10,5,"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",New York,332 255 9818,NY,9,1577750400,1619740800,10,United States,http://www.immunic-therapeutics.com,86400,10,1200 Avenue of the Americas,Biotechnology,Suite 200
t-2,IMUX,45715000,21749400,9987000,,-11458000,,-11458000,2235000,0,-12222000,-12222000,,,,,,0,0,12222000,0,764000,,-11458000,-11458000,160148000,8467000,78685000,205000,87152000,1000,-79856000,32970000,-1608000,42000,48607000,7674000,-1608000,1117000,53023000,1083000,1728000,297000,-55000,39212000,1559000,42116000,30029000,99000,-9227000,6000,-2904000,369000,-55000,45349000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,9.93,1630526403,0.07999992,9.88,10.18,9.74,82819,"Immunic, Inc.",NMS,PRE,-0.24559027,0,False,False,0.81218195,9.74 - 10.18,9.85,0.0,0.0,8,9,finmb_403013221,NasdaqGS,"Immunic, Inc.",USD,236998,156457,2.2400002,0.29128742,7.69 - 28.214,-18.284,-0.6480471,7.69,28.214,1555286400,1614346200,1614346200,1614346200,-2.81,-3.66,2,-3.96,-2.5075758,7.501,9.436571,0.49342918,0.052289035,13.162609,-3.2326088,215971552,-2.7131147,1.3238236,15,America/New_York,EDT,-14400000,2.03,,,28.21,7.69,9.44,13.16,237k,156.46k,21.75M,,14.09M,29.67%,46.06%,1.45M,9.05,7.68%,6.68%,931.78k,,,,,,0.00%,"Apr 14, 2019",,1:40,"Apr 14, 2019","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-26.18%,-40.54%,,,,,-48.93M,-44.02M,-2.81,,127.45M,6.02,973k,0.61,15.93,7.50,-46.12M,-30.37M,Value,10036,Healthcare,28,10,5,"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",New York,332 255 9818,NY,9,1577750400,1619740800,10,United States,http://www.immunic-therapeutics.com,86400,10,1200 Avenue of the Americas,Biotechnology,Suite 200
t-3,IMUX,17518000,21749400,6434000,,-8487000,,-8487000,2580000,0,-9014000,-9014000,,,,,,0,0,9014000,0,527000,,-8487000,-8487000,120567000,6804000,50488000,739000,57292000,1000,-68398000,32970000,-1682000,42000,18578000,6333000,-1682000,681000,23599000,641000,1432000,-973000,-4000,568000,-1936000,605000,-10791000,-326000,-11029000,14000,-37000,353000,-4000,17266000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,9.93,1630526403,0.07999992,9.88,10.18,9.74,82819,"Immunic, Inc.",NMS,PRE,-0.24559027,0,False,False,0.81218195,9.74 - 10.18,9.85,0.0,0.0,8,9,finmb_403013221,NasdaqGS,"Immunic, Inc.",USD,236998,156457,2.2400002,0.29128742,7.69 - 28.214,-18.284,-0.6480471,7.69,28.214,1555286400,1614346200,1614346200,1614346200,-2.81,-3.66,2,-3.96,-2.5075758,7.501,9.436571,0.49342918,0.052289035,13.162609,-3.2326088,215971552,-2.7131147,1.3238236,15,America/New_York,EDT,-14400000,2.03,,,28.21,7.69,9.44,13.16,237k,156.46k,21.75M,,14.09M,29.67%,46.06%,1.45M,9.05,7.68%,6.68%,931.78k,,,,,,0.00%,"Apr 14, 2019",,1:40,"Apr 14, 2019","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-26.18%,-40.54%,,,,,-48.93M,-44.02M,-2.81,,127.45M,6.02,973k,0.61,15.93,7.50,-46.12M,-30.37M,Value,10036,Healthcare,28,10,5,"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",New York,332 255 9818,NY,9,1577750400,1619740800,10,United States,http://www.immunic-therapeutics.com,86400,10,1200 Avenue of the Americas,Biotechnology,Suite 200
